Cutaneous melanoma is responsible for most deaths from skin cancers with survival rates depending on tumor stage at the time of diagnosis, which depends on the depth of the tumor (Breslow), as well as lymph node involvement or distant metastasis. Non-melanoma skin cancer includes a heterogeneous group of malignancies including basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and cutaneous adnexal tumors. Although mortality is low, due to the high incidence, the absolute number of deaths is comparable to melanoma. In the majority of cases these tumors present as localized tumors and are treated with curative surgery or radiotherapy, however, they can also present in an advanced or metastatic stage thus requiring systemic treatments. In the last decade, the therapeutic landscape has recently expanded with the development of immunotherapy and targeting therapies.
The goal of this Research Topic is to provide a complete overview of the role of immunotherapy and targeting therapies in the management of advanced cutaneous carcinomas. Further we aim to provide an update on the approvals for immunotherapy and targeting therapies for the treatment of advanced melanoma and advanced non-melanoma skin cancers with a focus on basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma. Ongoing trials and real-world evidence investigating the role of these treatments in the adjuvant, neoadjuvant settings as well as new challenges in the field should also be discussed.
Here, we are interested in the following themes:
• Current treatment options for metastatic melanoma (review article)
• The role of immunotherapy for the treatment of advanced squamous cell carcinoma (review article)
• Treatment options for locally advanced and metastatic basal cell carcinoma: challenges and perspectives
• Merkel cell carcinoma: therapeutic update
It is with deepest sorrow that we share with you the passing of our co-editor Professor Gabriella Fabbrocini, to whom we dedicate this collection.
Cutaneous melanoma is responsible for most deaths from skin cancers with survival rates depending on tumor stage at the time of diagnosis, which depends on the depth of the tumor (Breslow), as well as lymph node involvement or distant metastasis. Non-melanoma skin cancer includes a heterogeneous group of malignancies including basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and cutaneous adnexal tumors. Although mortality is low, due to the high incidence, the absolute number of deaths is comparable to melanoma. In the majority of cases these tumors present as localized tumors and are treated with curative surgery or radiotherapy, however, they can also present in an advanced or metastatic stage thus requiring systemic treatments. In the last decade, the therapeutic landscape has recently expanded with the development of immunotherapy and targeting therapies.
The goal of this Research Topic is to provide a complete overview of the role of immunotherapy and targeting therapies in the management of advanced cutaneous carcinomas. Further we aim to provide an update on the approvals for immunotherapy and targeting therapies for the treatment of advanced melanoma and advanced non-melanoma skin cancers with a focus on basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma. Ongoing trials and real-world evidence investigating the role of these treatments in the adjuvant, neoadjuvant settings as well as new challenges in the field should also be discussed.
Here, we are interested in the following themes:
• Current treatment options for metastatic melanoma (review article)
• The role of immunotherapy for the treatment of advanced squamous cell carcinoma (review article)
• Treatment options for locally advanced and metastatic basal cell carcinoma: challenges and perspectives
• Merkel cell carcinoma: therapeutic update
It is with deepest sorrow that we share with you the passing of our co-editor Professor Gabriella Fabbrocini, to whom we dedicate this collection.
